-
SpCas9 mRNA: Identity, Mechanism, and Evidence Limits
2026-10-16
APExBIO describes SpCas9 mRNA (ARCA, 5mCTP, ψUTP) as a modified messenger RNA encoding Streptococcus pyogenes Cas9 for guide-directed genome editing in eukaryotic research systems. The product description supports an intended molecular role, but it does not provide identity-matched evidence for translation, DNA cleavage, editing efficiency, specificity, cellular responses, or performance across models.
-
Tetraethylammonium Chloride: Scope and Evidence
2026-10-16
Tetraethylammonium chloride (TEAC) is cataloged by APExBIO as a tetraethylammonium-ion source and potassium-channel pore blocker. The available product information supports a conceptual account of pore-level ion-conduction studies and describes vascular, autonomic, and historical clinical contexts, but it does not provide identity-matched quantitative research evidence, channel-subtype selectivity data, or treatment-level conclusions.
-
SEA0400: What the Product Record Supports
2026-10-15
The APExBIO product page identifies SEA0400 as a Na+-Ca2+ exchanger inhibitor and attributes to it nanomolar inhibition of Na+-dependent Ca2+ uptake in cultured neural and glial cells, alongside reported selectivity claims and disease-model applications. Because no identity-matched research paper is available here, those statements should be treated as supplier-documented claims rather than independently verified study findings.
-
Tropisetron Hydrochloride: Evidence and Scope
2026-10-15
The APExBIO product page identifies Tropisetron Hydrochloride (SKU B2258; SDZ-ICS 930) as a reported 5-HT3 receptor antagonist and α7-nicotinic receptor agonist, with a supplier-reported 5-HT3 IC50 of 70.1 ± 0.9 nM. Because no identity-matched research paper is available, these claims should be treated as product documentation rather than independently verified evidence of receptor selectivity, downstream signaling, or translational effect.
-
DMOG in a Multilevel Bone-Regeneration Scaffold
2026-10-14
This editorial examines a 2026 study of a dual-material, 3D-bioprinted scaffold that combined mechanical support with osteogenic and angiogenic signaling. The study identified Dimethyloxalylglycine (DMOG) as part of a nanoparticle-mediated strategy associated with HIF-1α, vascularization, and bone formation, while distinguishing those findings from supplier-level claims about DMOG and from evidence that remains model-specific.
-
Mitochondria Isolation Kit: Evidence and Scope
2026-10-14
The APExBIO Mitochondria Isolation Kit (Cultured Cells), SKU K1138, is described as a research product for isolating mitochondria from cultured eukaryotic cells. Its stated conceptual scope includes mitochondrial protein analysis, apoptosis research, cell signaling studies, and investigations of mitochondrial physiological function. No matched paper or independent performance data were available for this overview.
-
HLY78 and Oral Fibrosis: Evidence Gaps
2026-10-13
Current evidence does not provide a head-to-head comparison of HLY78 with SFRP1 or establish HLY78 as a treatment-relevant compound in oral submucous fibrosis. The available literature instead juxtaposes a disease-model study of SFRP1 suppression of Wnt/β-catenin signaling with supplier-reported findings describing HLY78 as a Wnt/β-catenin pathway modulator in developmental models.
-
OmpA, Mitochondria and Chlamydial Apoptosis
2026-10-13
A 2026 PLOS Pathogens study proposes that Chlamydia-derived vesicles transport OmpA to mitochondrial membranes, where it engages BAK and suppresses BAX/BAK-dependent apoptosis. The evidence is mechanistically coherent but remains primarily cellular and does not establish clinical relevance or show that S63845 was used.
-
HEPES and the Limits of Rabbit Pharming Evidence
2026-10-12
Song et al. reported heritable, CSN2-promoter-directed tdTomato expression in rabbits, with a reported milk concentration of 15–20 g/L in homozygous animals. The result is a proof of concept for targeted rabbit pharming, but it does not show that HEPES, intracellular pH modulation, lysosomal biogenesis support, or the same expression level applies to therapeutic proteins.
-
2-Hydroxypropyl-β-cyclodextrin: Evidence Scope
2026-10-12
2-Hydroxypropyl-β-cyclodextrin is a hydroxypropylated beta-cyclodextrin described by APExBIO as a water-compatible cyclic oligosaccharide intended for conceptual use in solubility and formulation research. The available dossier supports its identity and proposed inclusion-complex role, but provides no compound-specific study establishing efficacy, bioavailability, pharmacokinetics, safety, or therapeutic value.
-
QX77 and the Next Frontier of Autophagy Translation
2026-10-10
QX77 provides a research-focused lens on LAMP2A, Rab11, and stem-cell state regulation, while a recent ETS1 study highlights how HSPA8-linked quality-control mechanisms may shape lung injury. This article separates established findings from translational hypotheses and outlines where a molecular chaperone activator can inform, but not substitute for, disease-specific validation.
-
InstaBlue Protein Stain Solution: Product Overview
2026-10-10
InstaBlue Protein Stain Solution (SKU B8226) is an APExBIO-listed Coomassie Brilliant Blue protein stain for conceptual use in visualizing protein bands in polyacrylamide gels. No matched paper evidence was supplied, so performance and application claims remain unindependently verified.
-
miR-24-3p, Sp1/PI3K, and Doxorubicin Heart Failure
2026-10-09
The reference study identifies miR-24-3p as a negative regulator in doxorubicin-induced heart failure and connects its effects to the Sp1/PI3K signaling axis. Using complementary rat and H9c2 cardiomyocyte models, the authors link miR-24-3p manipulation with cardiac dysfunction, apoptosis, oxidative stress, and direct targeting of Sp1, while leaving important questions about human translation unresolved.
-
Cinoxacin: Mechanism, Spectrum, and Clinical Evidence
2026-10-09
The 1982 reference paper synthesized evidence on Cinoxacin’s DNA-synthesis inhibition, activity against urinary pathogens, pharmacokinetics, safety, and clinical performance. Its main contribution was to connect microbiological activity with rapid urinary exposure and early evidence for treating and preventing recurrent urinary tract infections, while also documenting important limits such as cross-resistance and weak activity against Pseudomonas and Gram-positive organisms.
-
Multifunctional Hydrogels for Diabetic Wound Repair
2026-10-08
A source-grounded overview of a 2026 MnO₂ nanozyme and calcium-responsive hydrogel study, covering its research rationale, reported in vitro and diabetic-mouse findings, evidence strength, assay interpretation, and limitations for clinical translation.